Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
VIP: Evidence Summary
Evidence summary for VIP across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to VIP overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Pulmonary hypertension | Tier C | 2 | Inhaled VIP reduces pulmonary artery pressure in small trials |
| GI motility disorders | Tier C | 2 | Regulates intestinal motility and secretion; clinical applications in functional GI disorders |
| Neuroprotection | Tier D | 1 | Anti-inflammatory effects in neuroinflammation models; human data limited |